JP2015513543A - 癌および他の状態を処置するためのナノ構造体 - Google Patents

癌および他の状態を処置するためのナノ構造体 Download PDF

Info

Publication number
JP2015513543A
JP2015513543A JP2014558893A JP2014558893A JP2015513543A JP 2015513543 A JP2015513543 A JP 2015513543A JP 2014558893 A JP2014558893 A JP 2014558893A JP 2014558893 A JP2014558893 A JP 2014558893A JP 2015513543 A JP2015513543 A JP 2015513543A
Authority
JP
Japan
Prior art keywords
cells
cholesterol
hdl
nanostructure
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014558893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513543A5 (enExample
Inventor
シー． シャッド サクストン，
シー． シャッド サクストン，
マリナ ジー． ダミアーノ，
マリナ ジー． ダミアーノ，
ヘン チャン，
ヘン チャン，
ケイリン エム． マクマホン，
ケイリン エム． マクマホン，
シュオ ヤン，
シュオ ヤン，
レオ アイ． ゴードン，
レオ アイ． ゴードン，
アマレッシュウォー ティー．ケー． シン，
アマレッシュウォー ティー．ケー． シン，
Original Assignee
ノースウェスタン ユニバーシティ
ノースウェスタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースウェスタン ユニバーシティ, ノースウェスタン ユニバーシティ filed Critical ノースウェスタン ユニバーシティ
Publication of JP2015513543A publication Critical patent/JP2015513543A/ja
Publication of JP2015513543A5 publication Critical patent/JP2015513543A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ceramic Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2014558893A 2012-02-22 2013-02-22 癌および他の状態を処置するためのナノ構造体 Pending JP2015513543A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601706P 2012-02-22 2012-02-22
US61/601,706 2012-02-22
PCT/US2013/027431 WO2013126776A1 (en) 2012-02-22 2013-02-22 Nanostructures for treating cancers and other conditions

Publications (2)

Publication Number Publication Date
JP2015513543A true JP2015513543A (ja) 2015-05-14
JP2015513543A5 JP2015513543A5 (enExample) 2016-04-07

Family

ID=47833440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014558893A Pending JP2015513543A (ja) 2012-02-22 2013-02-22 癌および他の状態を処置するためのナノ構造体

Country Status (11)

Country Link
US (1) US20150064255A1 (enExample)
EP (2) EP3597209A1 (enExample)
JP (1) JP2015513543A (enExample)
KR (1) KR20140123597A (enExample)
CN (1) CN104244965A (enExample)
AU (1) AU2013222238A1 (enExample)
CA (1) CA2865279C (enExample)
ES (1) ES2745208T3 (enExample)
IN (1) IN2014DN07888A (enExample)
MX (1) MX2014010161A (enExample)
WO (1) WO2013126776A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022518479A (ja) * 2019-01-24 2022-03-15 ノースウェスタン ユニバーシティ 脂質結合体化コア足場を使用する高密度リポタンパク質模倣ナノ粒子
JP2022548895A (ja) * 2019-09-18 2022-11-22 ノースウェスタン ユニバーシティ がんにおけるフェロトーシス誘導剤としての高密度リポタンパク質様ナノ粒子

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5204646B2 (ja) 2005-04-25 2013-06-05 マサチューセッツ インスティテュート オブ テクノロジー 止血および他の生理学的活性を促進するための組成物および方法
ES2673947T3 (es) 2006-04-25 2018-06-26 Massachusetts Institute Of Technology Composiciones y métodos para afectar al movimiento de contaminantes, líquidos corporales u otras entidades y/o afectar a otras condiciones fisiológicas
CN102036652B (zh) 2008-04-25 2016-04-13 西北大学 适于螯合胆甾醇的纳米结构
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
US20130034599A1 (en) 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
JP2016504050A (ja) 2013-01-17 2016-02-12 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
WO2016011049A2 (en) * 2014-07-14 2016-01-21 Schwendeman Anna Compositions and methods for disease treatment using nanoparticle delivered compounds
WO2016057549A1 (en) 2014-10-06 2016-04-14 Aurasense Therapeutics, Llc Anti-tnf compounds
US10517924B2 (en) * 2014-11-24 2019-12-31 Northwestern University High density lipoprotein nanoparticles for inflammation
WO2016123365A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
US10967072B2 (en) 2016-04-27 2021-04-06 Northwestern University Short interfering RNA templated lipoprotein particles (siRNA-TLP)
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
JP2022529506A (ja) * 2019-04-26 2022-06-22 ノースウェスタン ユニバーシティ 眼の治療のための高密度リポタンパク質ナノ粒子およびｒｎａテンプレート化リポタンパク質粒子
US20220218788A1 (en) * 2019-05-10 2022-07-14 Northwestern University Orally delivered lipid nanoparticles target and reveal gut cd36 as a master regulator of systemic lipid homeostasis with differential gender responses
CN112569207A (zh) * 2019-09-30 2021-03-30 复旦大学 一种载脂蛋白修饰的仿生纳米肿瘤疫苗及其制备方法和用途
WO2023243865A1 (ko) * 2022-06-13 2023-12-21 (주) 멥스젠 약물전달용 재구축 고밀도 지단백 나노입자

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507807A (ja) * 2007-12-12 2011-03-10 ユニバーシティ・ヘルス・ネットワーク 高密度リポタンパク質様ペプチド−リン脂質足場（「ｈｐｐｓ」）ナノ粒子
JP2011518826A (ja) * 2008-04-25 2011-06-30 ノースウェスタン、ユニバーシティ コレステロールを隔離するのに適したナノ構造体
WO2011091065A2 (en) * 2010-01-19 2011-07-28 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007210034A1 (en) * 2006-01-26 2007-08-09 University Of Massachusetts RNA silencing agents for use in therapy and nanotransporters for efficient delivery of same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507807A (ja) * 2007-12-12 2011-03-10 ユニバーシティ・ヘルス・ネットワーク 高密度リポタンパク質様ペプチド−リン脂質足場（「ｈｐｐｓ」）ナノ粒子
JP2011518826A (ja) * 2008-04-25 2011-06-30 ノースウェスタン、ユニバーシティ コレステロールを隔離するのに適したナノ構造体
WO2011091065A2 (en) * 2010-01-19 2011-07-28 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARLOS G LEON: "ALTERATIONS IN CHOLESTEROL REGULATION CONTRIBUTE 以下省略", THE PROSTATE, vol. V70, JPN5015004272, 1 January 2009 (2009-01-01), pages 390 - 400, ISSN: 0003449877 *
GONCALVES ROMELIA PINHEIRO: "UPTAKE OF HIGH DENSITY LIPOPROTEIN (HDL) CHOLESTERYL ESTERS BY HUMAN ACUTE LEUKEMIA CELLS", LEUKEMIA RESEARCH, vol. V29 N8, JPN5015004266, 1 August 2005 (2005-08-01), US, pages 955 - 959, ISSN: 0003449878 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022518479A (ja) * 2019-01-24 2022-03-15 ノースウェスタン ユニバーシティ 脂質結合体化コア足場を使用する高密度リポタンパク質模倣ナノ粒子
JP7546927B2 (ja) 2019-01-24 2024-09-09 ノースウェスタン ユニバーシティ 脂質結合体化コア足場を使用する高密度リポタンパク質模倣ナノ粒子
JP2022548895A (ja) * 2019-09-18 2022-11-22 ノースウェスタン ユニバーシティ がんにおけるフェロトーシス誘導剤としての高密度リポタンパク質様ナノ粒子

Also Published As

Publication number Publication date
CN104244965A (zh) 2014-12-24
EP2817024B1 (en) 2019-07-10
EP3597209A1 (en) 2020-01-22
IN2014DN07888A (enExample) 2015-04-24
KR20140123597A (ko) 2014-10-22
WO2013126776A1 (en) 2013-08-29
ES2745208T3 (es) 2020-02-28
MX2014010161A (es) 2015-03-09
US20150064255A1 (en) 2015-03-05
AU2013222238A1 (en) 2014-09-18
EP2817024A1 (en) 2014-12-31
CA2865279C (en) 2023-04-25
CA2865279A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
EP2817024B1 (en) Nanostructures for treating cancers
US20230381338A1 (en) Polyglutamated antifolates and uses thereof
JP5863670B2 (ja) 核酸および／または他の構成要素を含有している合成ナノ構造体
US20110177155A1 (en) Methods of delivery of agents to leukocytes and endothelial cells
KR20170046145A (ko) 리포솜 캡슐화 친화 약제
WO2018031979A1 (en) Alpha and gamma-d polyglutamated antifolates and uses thereof
US11969396B2 (en) IPA-3-loaded liposomes and methods of use thereof
US10413565B2 (en) Nanostructures for modulating intercellular communication and uses thereof
JP2025120344A (ja) がんにおけるフェロトーシス誘導剤としての高密度リポタンパク質様ナノ粒子
CN108883068B (zh) 乳癌治疗
WO2015168393A1 (en) Nanostructures for modulating intercellular communication and uses thereof
HK40078738A (en) Alpha and gamma-d polyglutamated antifolates and uses thereof
OA19187A (en) Polyglutamated antifolates and uses thereof.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180208